MedTrace Logo

Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease

NCT01120002 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-07-22

No results posted yet for this study

Summary

A double blind, placebo-controlled randomized study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Alzheimer's Disease

Conditions

Interventions

DRUG

Tamibarotene

Two Tamibarotene 2 mg or placebo tablet per day, once daily.

DRUG

Placebo

Two Tamibarotene 2 mg or placebo tablet per day, once daily.

Sponsors & Collaborators

  • Osaka City University

    lead OTHER

Principal Investigators

  • Takami Miki, M.D. · Department of Geriatrics and Neurology, Osaka City University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01120002 on ClinicalTrials.gov